Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/14/2021 | $13.00 → $9.50 | Buy → Neutral | Mizuho |
| 9/9/2021 | $10.00 → $9.50 | Buy → Hold | Jefferies |
| 7/19/2021 | $8.00 → $9.00 | Outperform | Oppenheimer |
Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton's expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programsDevelopment to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizuresOvid to invest $10 million in preferred equity in Graviton and will fund development programsTransaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sales NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancer's (SITC 2021) 36th Annual Meeting, taking place virtually November 10 - 14, 2021.Details of the presentations are outlined below.Poster PresentationTitle: Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in metastatic and advanced solid tumorsTimes: Friday, November 12, 2021 - Sunday, November 14, 2021, 7:00 a.m. - 5:00 p.m.
SC 13D - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following
NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021."The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living with cGVHD. REZUROCK represents a paradigm shift in the cGVHD treatment landscape by uniquely addressing both the immune and fibrotic components of the disease," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month."Dr. Waksal added, "Our momentum continues as we advance our portfolio of p
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021."We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA goal date of August 30, 2021. Labeling discussions with the FDA are progressing and we believe that belumosudil, if approved, will serve a critical, unmet need for patients with cGVHD," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "In addition, we are exploring the therapeutic potential of belumosudil in systemic sclerosis, a disease with similar manifestations to cGVHD. We continue to
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
15-12B - Kadmon Holdings, Inc. (0001557142) (Filer)
EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)
EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)
Mizuho downgraded Kadmon Holdings from Buy to Neutral and set a new price target of $9.50 from $13.00 previously
Jefferies downgraded Kadmon Holdings from Buy to Hold and set a new price target of $9.50 from $10.00 previously
Oppenheimer reiterated coverage of Kadmon Holdings with a rating of Outperform and set a new price target of $9.00 from $8.00 previously
NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities relating to the potential regulatory approval of belumosudil for chronic graft-versus-host disease and lead the Company's clinical team to advance the development of additional product candidates. Dr. Cooper succeeds John Ryan, M.D., Ph.D., who will remain with the Company and transition to the role of Executive Medical Director, Clinical and Regulatory Development, where he will continue to advise on c